Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents

被引:4
|
作者
Kawata-Shimamura, Yumiko [1 ,2 ,3 ]
Eguchi, Hidetaka [2 ,4 ]
Kawabata-Iwakawa, Reika [5 ]
Nakahira, Mitsuhiko [1 ]
Okazaki, Yasushi [2 ,4 ]
Yoda, Tetsuya [3 ,6 ]
Grenman, Reidar [7 ,8 ]
Sugasawa, Masashi [1 ]
Nishiyama, Masahiko [2 ,9 ,10 ]
机构
[1] Saitama Med Univ, Int Med Ctr, Dept Head & Neck Surg, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Saitama Med Univ, Res Ctr Genom Med, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[3] Saitama Med Univ, Dept Oral Surg, 38 Morohongo, Moroyama, Saitama 3500495, Japan
[4] Juntendo Univ, Intractable Dis Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1130033, Japan
[5] Gunma Univ Initiat Adv Res, Div Integrated Oncol Res, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan
[6] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Maxillofacial Surg, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan
[7] Univ Turku, Dept Otorhinolaryngol Head & Neck Surg, POB 52, Turku 20521, Finland
[8] Turku Univ Hosp, POB 52, Turku 20521, Finland
[9] Gunma Univ, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan
[10] Higashi Sapporo Hosp, Shiroishi Ku, 7-35,3-3 Higashi Sapporo, Sapporo, Hokkaido 0038585, Japan
关键词
Predictive biomarker of response; Hypopharyngeal cancer; Drug therapy; Precision medicine; Molecular target; SQUAMOUS-CELL CARCINOMA; HEAD; CISPLATIN; TARGET; GROWTH; LARYNX; LINES;
D O I
10.1186/s12885-022-09853-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Hypopharyngeal cancer is a relatively rare malignancy with poor prognosis. Current chemotherapeutic algorithm is still far from personalized medicine, and the identification of the truly active therapeutic biomarkers and/or targets is eagerly awaited. Methods Venturing to focus on the conventional key chemotherapeutic drugs, we identified the most correlative genes (and/or proteins) with cellular sensitivity to docetaxel (TXT), cisplatin (CDDP) and 5-fluorouracil (5-FU) in the expression levels, through 3 steps approach: genome-wide screening, confirmation study on the quantified expression levels, and knock-down and transfection analyses of the candidates. The probable action pathways of selected genes were examined by Ingenuity Pathway Analysis using a large-scale database, The Cancer Genome Atlas. Results The first genome-wide screening study derived 16 highly correlative genes with cellular drug sensitivity in 15 cell lines (|R| > 0.8, P < 0.01 for CDDP and 5-FU; |R| > 0.5, P < 0.05 for TXT). Among 10 genes the observed correlations were confirmed in the quantified gene expression levels, and finally knock-down and transfection analyses provided 4 molecules as the most potent predictive markers-AGR2 (anterior gradient 2 homolog gene), and PDE4D (phosphodiesterase 4D, cAMP-specific gene) for TXT; NINJ2 (nerve Injury-induced protein 2); CDC25B (cell division cycle 25 homolog B gene) for 5-FU- in both gene and protein expression levels. Overexpression of AGR2, PDE4D signified worse response to TXT, and the repressed expression sensitized TXT activity. Contrary to the findings, in the other 2 molecules, NINJ2 and CDC25, there observed opposite relationship to cellular drug response to the relevant drugs. IPA raised the potential that each selected molecule functionally interacts with main action pathway (and/or targets) of the relevant drug such as tubulin beta chain genes for TXT, DNA replication pathway for CDDP, and DNA synthesis pathway and thymidylate synthetase gene for 5-FU. Conclusion We newly propose 4 molecules -AGR2, PDE4D,NINJ2 and CDC25B) as the powerful exploratory markers for prediction of cellular response to 3 key chemotherapeutic drugs in hypopharyngeal cancers and also suggest their potentials to be the therapeutic targets, which could contribute to the development of precision medicine of the essential chemotherapy in hypopharyngeal patients. (339 words).
引用
收藏
页数:16
相关论文
共 49 条
  • [1] Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents
    Yumiko Kawata-Shimamura
    Hidetaka Eguchi
    Reika Kawabata-Iwakawa
    Mitsuhiko Nakahira
    Yasushi Okazaki
    Tetsuya Yoda
    Reidar Grénman
    Masashi Sugasawa
    Masahiko Nishiyama
    BMC Cancer, 22
  • [2] Cancer Biomarker Discovery for Precision Medicine: New Progress
    Zou, Jinfeng
    Wang, Edwin
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (42) : 7655 - 7671
  • [3] Exosome-Based Theranostic for Gastrointestinal Cancer: Advances in Biomarker Discovery and Therapeutic Engineering
    Mehta, Mohit J.
    Shin, Dongjun
    Park, Hyun Sung
    An, Jun Su
    Lim, Seong Il
    Kim, Hyun Jin
    Hong, Seungpyo
    Bu, Jiyoon
    SMALL METHODS, 2025,
  • [4] A flexible pipeline for precision medicine biomarker detection and prediction of treatment response
    Hughitt, V. Keith
    Gorjifard, Sayeh
    Michalowski, Aleksandra M.
    Simmons, John K.
    Dale, Ryan
    Polley, Eric C.
    Keats, Jonathan J.
    Mock, Beverly A.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] OCTAD: An open cancer therapeutic discovery workspace in the era of precision medicine
    Chen, Bin
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Fibroblast growth factor receptor-2 cancer models for biomarker discovery and therapeutic response prediction
    Kabbarah, Omar
    Lerner, Lorena
    Siddiquee, Zakir
    Li, Guangmu
    Zhao, Jianhua
    Yang, John
    Zarycki, Jodi
    Weng, Zhigang
    Kollipara, Sriram
    Kannan, Karuppiah
    Yalavarthi, Sireesha
    Clark, Steven
    Gyuris, Jeno
    Robinson, Murray
    Chiu, M.
    CANCER RESEARCH, 2009, 69
  • [7] Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine
    Wang, Hao
    Jiang, Na
    Zhang, Yali
    Chen, Ruibing
    CANCER BIOLOGY & MEDICINE, 2019, 16 (04) : 623 - 629
  • [8] Clinical proteomics:a driving force for cancer therapeutic target discovery and precision medicine
    Hao Wang
    Na Jiang
    Yali Zhang
    Ruibing Chen
    CancerBiology&Medicine, 2019, 16 (04) : 623 - 629
  • [9] Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine
    Chandran, Vinod
    Rahman, Proton
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (01): : 35 - 42
  • [10] Impact of hemolysis on multiomic pancreatic cancer biomarker discovery: De-risking precision medicine biomarker development
    Kiebish, Michael A.
    Shah, Punit
    Bussberg, Valerie
    Tolstikov, Vladimir
    Searfoss, Rick
    Ofori-Mensa, Kennedy
    Grund, Eric M.
    Darkwah, Abena
    Chen, Emily Y.
    Greenwood, Bennett
    Ntoso, Ellaine Adu
    Rodrigues, Leonardo
    Liu, Mia
    Granger, Elder
    Bountra, Chas
    Sarangarajan, Rangaprasad
    Moser, A. J.
    Narain, Niven R.
    CANCER RESEARCH, 2020, 80 (16)